Analyst Ratings for BridgeBio Oncology Therapeutics, In (BBOT)
BBOT Rating Summary
BBOT Price Target Summary
- Highest: $32.00 (Leerink)
- Lowest: $20.00 (Morgan Stanley)
- Average: $24.75
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$24.75 (+180.6%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/8/2026 | JPMorgan » Updated 8/14/2026 |
Priyanka Grover | New Coverage | Overweight (N/A) |
25.00 (27.00) |
8.41 (8.82) |
4.88% | Details |
| 6/22/2026 | Oppenheimer | Mazahir Alimohamed | New Coverage | Outperform (Outperform) |
22.00 (N/A) |
7.56 (8.82) |
16.67% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
